Stimulation of cholecystokinin-A receptors with Gl181771X: A failed clinical trial that did not test the pharmacogenetic hypothesis for reduction of food intake

Clinical Pharmacology and Therapeutics

Volumn 85, Issue 4, 2009, Pages 362-365

  Roses, A D ^a,b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Cabernet Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLECYSTOKININ A RECEPTOR; CHOLECYSTOKININ B RECEPTOR; GI 181771;

CALORIC RESTRICTION; DRUG EFFICACY; DRUG MECHANISM; ENERGY BALANCE; FOOD AND DRUG ADMINISTRATION; FOOD INTAKE; GENOTYPE; HUMAN; MEDICAL RESEARCH; NOTE; OBESITY; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PUBLICATION; SINGLE NUCLEOTIDE POLYMORPHISM;

BENZODIAZEPINES; EATING; HUMANS; PHARMACOGENETICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, CHOLECYSTOKININ A; WEIGHT LOSS;

EID: 62649127050     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2008.192     Document Type: Note

References (17)

1. Jordan, J. et al. Stimulation of cholecystokinin-A receptors with GI181771X does not cause weight loss in overweight or obese patients. Clin. Pharmacol. Ther. 83, 281-287 (2008).
2. Stevens, V.J. et al. Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II [comment]. Ann. Intern. Med. 134, 1-11 (2001).
3. Liddle, R.A., Goldfine, I.D., Rosen, M.S., Taplitz, R.A. & Williams, J.A. Cholecystokinin bioactivity in human plasma. Molecular forms, responses to feeding, and relationship to gallbladder contraction. J. Clin. Invest. 75, 1144-1152 (1985).
4. Noble, F. et al. International Union of Pharmacology, XXI. Structure, distribution, and functions of cholecystokinin receptors [published erratum appears in Pharmacol. Rev. 52, 177 (2000)]. Pharmacol. Rev. 51, 745-781 (1999).
5. de Weerth, A., Pisegna, J.R., Huppi, K. & Wank, S.A. Molecular cloning, functional expression and chromosomal localization of the human cholecystokinin type A receptor. Biochem. Biophys. Res. Commun. 194, 811-818 (1993).
6. Moran, T.H., Kinzig, K.P., Moran, T.H. & Kinzig, K.P. Gastrointestinal satiety signals II. Cholecystokinin. Am. J. Physiol. Gastrointest. Liver Physiol. 286, G183-G188 (2004).
7. Cox, J.E., Randich, A., Cox, J.E. & Randich, A. CCK-8 activates hepatic vagal C-fiber afferents. Brain Res. 776, 189-194 (1997).
8. Moran, T.H. et al. Central and peripheral vagal transport of cholecystokinin binding sites occurs in afferent fibers. Brain Res. 526, 95-102 (1990).
9. Roses, A.D. Pharmacogenetics and drug development: the path to safer and more effective drugs. Nat. Rev. Genet. 5, 645-656 (2004).
10. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls [comment]. Nature 447, 661-678 (2007).
11. Hoh, J. et al. SNP haplotype tagging from DNA pools of two individuals. BMC Bioinformatics 4, 14 (2003).
12. Lesko, L.J. & Lesko, L.J. Paving the critical path: how can clinical pharmacology help achieve the vision? Clin. Pharmacol. Ther. 81, 170-177 (2007).
13. Risner, M.E. et al. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease [comment]. Pharmacogenomics J. 6, 246-254 (2006).
14. Roses, A.D. et al. Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease). Pharmacogenomics J. 7, 10-28 (2007).
15. Roses, A.D. Pharmacogenetics in drug discovery and development: a translational perspective. Nat. Rev. Drug Discov. 7, 807-817 (2008).
16. Orr, M.S. et al. The experience with voluntary genomic data submissions at the FDA and a vision for the future of the voluntary data submission program. Clin. Pharmacol. Ther. 81, 294-297 (2007).
17. Reichert, J.M. & Reichert, J.M. Trends in development and approval times for new therapeutics in the United States. Nat. Rev. Drug Discov. 2, 695-702 (2003).